View in EDS

Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression.

Saved in:
Bibliographic Details
Title: Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression.
Authors: Codocedo JF; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Mera-Reina C; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Lin PB; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Puntambekar SS; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Casali BT; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Jury N; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Martinez P; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Lasagna-Reeves CA; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA., Landreth GE; Stark Neurosciences Research Institute, Indiana University, School of Medicine, Indianapolis, IN 46202, USA.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2023 Nov 15. Date of Electronic Publication: 2023 Nov 15.
Publication Type: Preprint; Journal Article
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2023.11.11.566270